Eileen F Dunne1, Allison Naleway2, Ning Smith2, Bradley Crane2, Sheila Weinmann2, Jim Braxton1, Martin Steinau3, Elizabeth R Unger3, Lauri E Markowitz1. 1. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. 2. Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. 3. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 12-year-olds, and for young adults not previously vaccinated. Early vaccine impact can be measured by reductions in vaccine-type (VT) HPV prevalence. METHODS: Consecutive residual cervical specimens were retained from women aged 20-29 years at Kaiser Permanente Northwest in 2007, 2012, and 2013. HPV genotypes were determined using L1 consensus polymerase chain reaction with type-specific hybridization to detect 37 types, including VT HPV (HPV type 6, 11, 16, and 18). We compared HPV prevalence in 2007 and 2012-2013, and we evaluated predictors of VT HPV and any-HPV prevalence in 2012-2013. RESULTS: In 2012-2013, 31.9% of 4181 women had initiated HPV vaccination. VT HPV prevalence decreased from 10.6% in 2007 to 6.2% in 2012-2013 (P < .001). In 2012-2013, VT HPV prevalence was significantly lower among those who initiated vaccination <19 years (adjusted prevalence ratio, 0.1; 95% confidence interval, .1-.3) than among those who were not vaccinated, and higher among those who had chlamydia, human immunodeficiency virus, or pregnancy testing in the past year than among those who did not (adjusted prevalence ratio, 1.4; 95% confidence interval, 1.1-1.8). CONCLUSIONS: Reduction in VT HPV was found in young women in an integrated healthcare delivery system within 6 years of vaccine introduction, indicating early HPV vaccine impact.
BACKGROUND: In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 12-year-olds, and for young adults not previously vaccinated. Early vaccine impact can be measured by reductions in vaccine-type (VT) HPV prevalence. METHODS: Consecutive residual cervical specimens were retained from women aged 20-29 years at Kaiser Permanente Northwest in 2007, 2012, and 2013. HPV genotypes were determined using L1 consensus polymerase chain reaction with type-specific hybridization to detect 37 types, including VT HPV (HPV type 6, 11, 16, and 18). We compared HPV prevalence in 2007 and 2012-2013, and we evaluated predictors of VT HPV and any-HPV prevalence in 2012-2013. RESULTS: In 2012-2013, 31.9% of 4181 women had initiated HPV vaccination. VT HPV prevalence decreased from 10.6% in 2007 to 6.2% in 2012-2013 (P < .001). In 2012-2013, VT HPV prevalence was significantly lower among those who initiated vaccination <19 years (adjusted prevalence ratio, 0.1; 95% confidence interval, .1-.3) than among those who were not vaccinated, and higher among those who had chlamydia, human immunodeficiency virus, or pregnancy testing in the past year than among those who did not (adjusted prevalence ratio, 1.4; 95% confidence interval, 1.1-1.8). CONCLUSIONS: Reduction in VT HPV was found in young women in an integrated healthcare delivery system within 6 years of vaccine introduction, indicating early HPV vaccine impact.
Authors: Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Elissa Meites; Rachel L Winer; Michael E Newcomb; Pamina M Gorbach; Troy D Querec; Jessica Rudd; Tom Collins; John Lin; Janell Moore; Thomas Remble; Fred Swanson; Justin Franz; Robert K Bolan; Matthew R Golden; Brian Mustanski; Richard A Crosby; Elizabeth R Unger; Lauri E Markowitz Journal: J Infect Dis Date: 2020-11-13 Impact factor: 5.226
Authors: Rayleen M Lewis; Allison L Naleway; Nicola P Klein; Bradley Crane; Amber Hsiao; Laurie Aukes; Julius Timbol; Troy D Querec; Martin Steinau; Sheila Weinmann; Elizabeth R Unger; Lauri E Markowitz Journal: J Low Genit Tract Dis Date: 2022-04-01 Impact factor: 3.842
Authors: David Mesher; Kate Soldan; Matti Lehtinen; Simon Beddows; Marc Brisson; Julia M L Brotherton; Eric P F Chow; Teresa Cummings; Mélanie Drolet; Christopher K Fairley; Suzanne M Garland; Jessica A Kahn; Kimberley Kavanagh; Lauri Markowitz; Kevin G Pollock; Anna Söderlund-Strand; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Elizabeth Unger; Sara L Thomas Journal: Emerg Infect Dis Date: 2016-10 Impact factor: 6.883
Authors: Juan C Felix; Michael J Lacey; Jeffrey D Miller; Gregory M Lenhart; Mark Spitzer; Rucha Kulkarni Journal: J Womens Health (Larchmt) Date: 2016-03-29 Impact factor: 2.681